Your browser doesn't support javascript.
Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine rollout in a multi-site healthcare system.
Al-Obaydi, Sarah; Hennrikus, Eileen; Mohammad, Nazar; Lehman, Erik B; Thakur, Abhishek; Al-Shaikhly, Taha.
  • Al-Obaydi S; Department of Medicine, Division of Hospital Medicine, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.
  • Hennrikus E; Department of Medicine, Division of Hospital Medicine, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.
  • Mohammad N; Department of Medicine, Division of Hospital Medicine, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.
  • Lehman EB; Department of Public Health Science, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.
  • Thakur A; Harrisburg University of Science & Technology, Harrisburg, Pennsylvania, United States of America.
  • Al-Shaikhly T; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.
PLoS One ; 17(8): e0272691, 2022.
Article in English | MEDLINE | ID: covidwho-2079723
ABSTRACT

BACKGROUND:

Hesitancy and incomplete vaccination against coronavirus disease 2019 (COVID-19) remains an obstacle to achieving herd immunity. Because of fear of vaccine reactions, patients with medical and allergic co-morbidities express heightened hesitancy. Limited information is available to guide these patients. We sought to identify factors associated with mRNA-based COVID-19 vaccines hesitancy and reactogenicity.

METHODS:

We surveyed employees of a multi-site health system in central Pennsylvania who were offered the COVID-19 vaccine (N = 18,740) inquiring about their experience with the Moderna and Pfizer-BioNTech mRNA-based vaccines. The survey was administered online using the REDCap platform. We used multivariable regression analysis to determine whether a particular factor(s) (e.g., demographics, selected co-morbid allergic and medical conditions, vaccine brand, and prior COVID-19) were associated with vaccine reactogenicity including the occurrence and severity of local and systemic reactions. We also explored factors and reasons associated with vaccine hesitancy.

RESULTS:

Of the 5709 who completed the survey (response rate, 30.4%), 369 (6.5%) did not receive the vaccine. Black race and allergy to other vaccines were associated with vaccine hesitancy. Reaction intensity following the first vaccine dose and allergic co-morbidities were associated with incomplete vaccination. Older individuals (>60 years) experienced less reactogenicity. Females had higher odds of local and systemic reactions and reported more severe reactions. Asians reported more severe reactions. As compared to Pfizer-BioNTech, the Moderna vaccine was associated with higher odds of vaccine reactions of higher severity. Prior COVID-19 resulted in more severe reactions following the first dose, but less severe reactions following the second dose.

CONCLUSIONS:

Targeted campaigns to enhance vaccination acceptance should focus on Black individuals, females, and those with allergic co-morbidities. Prior COVID-19 caused more severe reactions after the first but not the second vaccine dose. Moderna vaccine caused more vaccine reactions. Lessons learned from the early rollout of COVID-19 vaccine may serve to inform future novel vaccine experiences.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Vaccination Hesitancy / Hypersensitivity Type of study: Observational study / Prognostic study / Qualitative research Topics: Vaccines Limits: Female / Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0272691

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Vaccination Hesitancy / Hypersensitivity Type of study: Observational study / Prognostic study / Qualitative research Topics: Vaccines Limits: Female / Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0272691